Answers are grounded in this paper and cite their sources.
ESPITE CONSIDERABLE advances in the treatment of hemophilia, clinical expertise in hemophilia care is often concentrated within hemophilia treatment centers. These centers directly and indirectly care for most patients with hemophilia, and provide sophisticated services to this patient population. Much as bone marrow transplantation (BMT) and transfusion medicine have earned a special niche in hematology as sub-subspecialties of the discipline of hematology, hemophilia care is often categorized similarly. Despite the centralization of hemophilia care, hematologists are often called on to deal with the emergency treatment of hemophilia and with the routine aspects of hemophilia treatment. Furthermore, understanding of the treatment of hemophilia is an integral component of hematology training. This review should be construed as a guide to current management issues in hemophilia treatment, to provide all hematologists with a basic foundation in this field. ELEMENTS OF HEMOPHILIA Hemophilia A is caused by the deficiency of factor VIII, hemophilia B is caused by the deficiency of factor IX. After activation of factor IX to factor IXa, this enzyme interacts with the active cofactor form of factor VIII, factor VIIIa, to form a complex on membrane surfaces. This complex converts factor X to factor Xa.’ Thus, both factor IX and factor VI11 are critical components of the blood coagulation pathways.* Each individual case of hemophilia is characterized by a series of unique parameters, emphasizing the variability and heterogeneity of this disease. These parameters include the mode of initial presentation, the baseline level of the clotting factor, and the presence or absence of a relevant family history. Major acute and chronic complications are often secondary to recurrent bleeding. Joint deformities, with attendent limitations of the range of motion, are among the most common problems. Patients, particularly those who have required long-term intensive therapy who have been treated with the older generation of factor concentrates, have been exposed to numerous viruses, including hepatitis and human immunodeficiency virus (HIV), and may have the infectious consequences of these exposure^.^.^ The development of an inhibitor greatly influences the treatment plan, the success of treatment, and the cost of treatment. The bleeding frequency and the frequency of the need for therapeutic intervention establishes a pattern for an individual case. In adults, analgesic use and abuse occur because of chronic joint pain. The education, motivation, and professional attainment of a patient provide insight concerning the degree to which the hemophilia disability has impacted on the career growth and societal contributions. Work or school absenteeism play an important role in impairing the success of an otherwise highly capable individual. Other patients with severe hemophilia are nonetheless able to reach the pinnacles of their professions and contribute significantly to society.
No takes yet. Share an insight, caveat, or question.
Furie et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: